1213 related articles for article (PubMed ID: 21132647)
21. Use of low-molecular-weight heparin to bridge therapy in obese patients and in patients with renal dysfunction.
George-Phillips KL; Bungard TJ
Pharmacotherapy; 2006 Oct; 26(10):1479-90. PubMed ID: 16999658
[TBL] [Abstract][Full Text] [Related]
22. Half-dose enoxaparin vs. full-dose enoxaparin for postoperative bridging therapy in patients after cardiac surgery: which dose regimen should be preferred?
Weiss A; Brose S; Ploetze K; Matschke K
Clin Hemorheol Microcirc; 2013 Jan; 54(3):249-58. PubMed ID: 23648452
[TBL] [Abstract][Full Text] [Related]
23. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
Holzheimer RG
Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
[TBL] [Abstract][Full Text] [Related]
24. Low molecular weight heparin in the treatment of venous and arterial thromboses in the premature infant.
Michaels LA; Gurian M; Hegyi T; Drachtman RA
Pediatrics; 2004 Sep; 114(3):703-7. PubMed ID: 15342842
[TBL] [Abstract][Full Text] [Related]
25. Pharmacodynamics of unfractionated heparin during and after a hemodialysis session.
Brunet P; Simon N; Opris A; Faure V; Lorec-Penet AM; Portugal H; Dussol B; Berland Y
Am J Kidney Dis; 2008 May; 51(5):789-95. PubMed ID: 18436089
[TBL] [Abstract][Full Text] [Related]
26. Comparison of safety of subcutaneous enoxaparin as outpatient anticoagulation bridging therapy in patients with a mechanical heart valve versus patients with nonvalvular atrial fibrillation.
Bui HT; Krisnaswami A; Le CU; Chan J; Shenoy BN
Am J Cardiol; 2009 Nov; 104(10):1429-33. PubMed ID: 19892063
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the effectiveness and safety of low-molecular weight heparin versus unfractionated heparin anticoagulation after heart valve surgery.
Bucci C; Geerts WH; Sinclair A; Fremes SE
Am J Cardiol; 2011 Feb; 107(4):591-4. PubMed ID: 21184996
[TBL] [Abstract][Full Text] [Related]
28. Early ambulation and variability in anticoagulation during elective coronary stenting with a single intravenous bolus of low-dose, low-molecular weight heparin enoxaparin.
Zalc S; Lemos PA; Esteves A; Ribeiro EE; Horta P; Nicolau JC; Ramires JA; Cohen M; Martinez EE
J Invasive Cardiol; 2006 Feb; 18(2):45-8. PubMed ID: 16446514
[TBL] [Abstract][Full Text] [Related]
29. Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane.
Lavaud S; Canivet E; Wuillai A; Maheut H; Randoux C; Bonnet JM; Renaux JL; Chanard J
Nephrol Dial Transplant; 2003 Oct; 18(10):2097-104. PubMed ID: 13679486
[TBL] [Abstract][Full Text] [Related]
30. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin).
Mismetti P; Laporte-Simitsidis S; Navarro C; Sié P; d'Azemar P; Necciari J; Duret JP; Gaud C; Decousus H; Boneu B
Thromb Haemost; 1998 Jun; 79(6):1162-5. PubMed ID: 9657442
[TBL] [Abstract][Full Text] [Related]
31. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
[TBL] [Abstract][Full Text] [Related]
32. Clinical safety and anticoagulation efficacy of low-molecular-weight heparins in chronic hemodialysis patients: a single medical center experience.
Chuang FR; Chen TC; Lee CH; Ng HY; Wang IK; Chang HW; Chuang PH; Wu CH; Yang CC; Su YJ
Ren Fail; 2011; 33(10):990-7. PubMed ID: 22013932
[TBL] [Abstract][Full Text] [Related]
33. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment.
Kruse MW; Lee JJ
Am Heart J; 2004 Oct; 148(4):582-9. PubMed ID: 15459586
[TBL] [Abstract][Full Text] [Related]
34. Anticoagulant effect at the time of epidural catheter removal in patients receiving twice-daily or once-daily low-molecular-weight heparin and continuous epidural analgesia after orthopedic surgery.
Douketis JD; Kinnon K; Crowther MA
Thromb Haemost; 2002 Jul; 88(1):37-40. PubMed ID: 12152674
[TBL] [Abstract][Full Text] [Related]
35. Low molecular weight heparin: a critical analysis of clinical trials.
Green D; Hirsh J; Heit J; Prins M; Davidson B; Lensing AW
Pharmacol Rev; 1994 Mar; 46(1):89-109. PubMed ID: 8190751
[TBL] [Abstract][Full Text] [Related]
36. Anticoagulant efficacy of PEG-Hirudin in patients on maintenance hemodialysis.
Pöschel KA; Bucha E; Esslinger HU; Ulbricht K; Nörtersheuser P; Stein G; Nowak G
Kidney Int; 2004 Feb; 65(2):666-74. PubMed ID: 14717940
[TBL] [Abstract][Full Text] [Related]
37. Low molecular weight heparin and bleeding in patients with chronic renal failure.
Crowther M; Lim W
Curr Opin Pulm Med; 2007 Sep; 13(5):409-13. PubMed ID: 17940486
[TBL] [Abstract][Full Text] [Related]
38. Clinical experience with nadroparin in patients undergoing dialysis for renal impairment.
Zhang W; Chen X; Chen Y; Chen N
Hemodial Int; 2011 Jul; 15(3):379-94. PubMed ID: 21722301
[TBL] [Abstract][Full Text] [Related]
39. Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?
Priglinger U; Delle Karth G; Geppert A; Joukhadar C; Graf S; Berger R; Hülsmann M; Spitzauer S; Pabinger I; Heinz G
Crit Care Med; 2003 May; 31(5):1405-9. PubMed ID: 12771610
[TBL] [Abstract][Full Text] [Related]
40. Prevention of venous thromboembolism in the rehabilitation phase after spinal cord injury: prophylaxis with low-dose heparin or enoxaparin.
Spinal Cord Injury Thromboprophylaxis Investigators
J Trauma; 2003 Jun; 54(6):1111-5. PubMed ID: 12813331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]